

# Interim Financial Report for Fiscal Year 2008 (Ended June 30, 2008)

August 6, 2008

Company Name: Carna Biosciences Inc.

Listed Securities Exchange: JQ • NEO

Stock Code: 4572 URL http://www.carnabio.com

Representative: Kohichiro Yoshino, President

Contact: Yutaka, Shimakawa, Director TEL (078)302-7039

Expected semiannual report submission date: September 29, 2008

(Rounding down to the nearest million yen)

## 1. Consolidated results for the interim FY2008 (January 1, 2008 to June 30, 2008)

# (1) Business Results (Consolidated) (% indicates the increase / decrease from previous interim fiscal year)

	Total Revenue	Operating income	Ordinary income	Net income for the
				interim fiscal year
	million yen %	million yen %	million yen %	million yen %
FY2008(interim)	238 -	-118 -	-167 -	-168 -
FY2007(interim)				
FY2007 as reference	-	-	-	-

	Interim net income	Interim net income	
	per share	per share (diluted)	
	yen	yen	
FY2008(interim)	-3,417.21	-	
FY2007(interim)	-	-	
FY2007 as reference	-	-	

## (2)Financial Condition (Consolidated)

	Total assets	Net assets	Equity ratio	Net assets per share	
	million yen	million yen million yen		Yen	
FY2008(interim)	2,365	2,173	91.9	40,859.96	
FY2007(interim)	-	-	-	-	
FY2007 as reference	-	-	-	-	

# (3)Cash Flow (Consolidated)

	Cash flow from operating activities	Cash flow from investing activities	Cash flow from financing activities	Cash and cash equivalents at the end-of-term
	million yen	million yen	million yen	million yen
FY2008(interim)	-104	-5	813	1,904
FY2007(interim)	-	-	-	-
FY2007 as reference	-	-	-	-

## 2. Cash Dividends

	Dividends per share					
(criterion)	End of first	End of interim End of third		End of FY	FY	
	quarterly period	FY	quarterly period			
	yen	yen	yen	yen	yen	
FY2008	-	0	-	-	0	
FY2007	-	0	-	0	0	
FY2008(forecast)	-	-	-	0	0	

# 3. Consolidated forecast for FY2008 (January 1, 2008 to December 31, 2008)

(%indicates the increase/decrease from previous fiscal year)

	Total revenue	Operating income	Ordinary income	Net income	Net income per
	million yen %	million yen %	million yen %	million yen %	Yen
FY2008	712 -	-284 -	-333 -	-592 -	-11,558.65

# (Reference) Summary of Non-Consolidated results

# 1. Non-Consolidated results for the interim FY2008 (January 1, 2008 to June 30, 2008)

## (1) Business Results (Non-Consolidated)

(% indicates the increase / decrease from previous interim fiscal year)

	Total Revenue	Operating income	Ordinary income	Net income for the	
				interim fiscal year	
	million yen %	million yen %	million yen %	million yen %	
FY2008(interim)	240 -9.3	-107 -	-156 -	-157 -	
FY2007(interim)	265 -	-47 -	-45 -	-48 -	
FY2007 as reference	513	-147	-158	-179	

	Interim net income per	
	share	
	yen	
FY2008(interim)	-3,199.06	
FY2007(interim)	-1,086.98	
FY2007 as reference	-4,042.02	

## (2) Financial Condition (Non-Consolidated)

	Total assets	Net assets	Equity ratio	Net assets per share	
	million yen	million yen	%	Yen	
FY2008(interim)	2,374	2,184	92.0	41,063.45	
FY2007(interim)	1,942	1,627	83.8	36,592.49	
FY2007 as reference	1,622	1,435	88.5	32,275.11	

#### 2. Non-Consolidated forecast for FY2008 (January 1, 2008 to December 31, 2008)

(%indicates the increase/decrease from previous fiscal year)

	Total revenue	Operating	Ordinary income	Net income	Net income per
	Total Tevenue	income	Ordinary income	Net income	share
	million yen %	million yen %	million yen %	million yen %	Yen
FY2008	674 -	-252 -	-301 -	-560 -	-10,933.85

# \*Disclaimer regarding appropriate use of forecasts and related points of note

- 1. The above-mentioned forecasts are based on the information available on the date of release of these materials and on various assumptions made on the date of release of these material including uncertain factors and may affect future earnings. Actual operating results may differ significantly from those forecasts as a consequence of various factors.
- 2. We have amended consolidated forecast and non-consolidated forecast for FY2008 according to the actual performance of interim period and forecasts of future performances. In addition, business forecasts of CarnaBio USA Inc. which became a consolidated subsidiary from June 2008, had been taken into account.